Proxi Biotech are a Danish biotech company founded in 2018 and spun-out from research at the Statens Serum Institut. Their proprietary toxoid antigen technology is designed to target high-priority, recurrent bacterial infections (such as those from Clostridium difficile and uropathogenic E. coli), supporting development of novel active immunotherapies for drug-resistant pathogens.